CIGB 300
Also known as: CB-300, CIGB-300, CIGB‑300, CIGB300
Source CIGB 300 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CIGB‑300 is a synthetic 15‑mer peptide that antagonizes protein kinase CK2 activity. It has been evaluated in early‑phase clinical trials for cervical cancer and other solid tumours.
Mechanism of Action
Blocks CK2-mediated phosphorylation of substrates, inducing apoptosis and inhibiting proliferation of tumor cells
Routes of Administration
Goals & Uses
- Inhibition of CK2-driven pro-survival signalingMolecular Target EngagementModerate
- Induction of apoptosis in tumor cellsCellular PharmacologyModerate
- solid tumorsOncologyLow
- Antitumor activity in cervical cancerOncologyModerate
- Antitumor activity in non-small cell lung cancerOncologyLow
- cervical cancerOncologyModerate
Contraindications
- Severe hypersensitivity to peptide componentsAllergy / ImmunologyHigh
- Severe hepatic or renal impairmentOrgan ImpairmentModerate
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Hypersensitivity to peptideAllergyHigh
Adverse Effects
- Local Injection Site ReactionsDermatologicalCommon
- Injection site painLocalCommonPain at the injection site
- Fever / flu-like symptomsSystemicUncommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
- Hematologic toxicityHematologyRare
Drug Interactions
- Cytochrome P450 substratesLow
- Other CK2 inhibitorsModerate
- ImmunosuppressantsLowPotential interaction with immune pathways or infection risk
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Pregnant womenReproductiveAbsolute
- Patients with autoimmune disordersImmunologicalRelative
Regulatory Status
- European UnionInvestigationalClinical trials under EMA oversight
- CUInvestigationalDeveloped in Cuba, not yet marketed
- United StatesInvestigationalIND holder, phase I/II trials ongoing
- United KingdomInvestigationalNot approved by MHRA; investigational use only.
Investigational new drug (IND) status in the US and EU; not approved for any indication.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is CIGB 300?
CIGB‑300 is a synthetic 15‑mer peptide that antagonizes protein kinase CK2 activity. It has been evaluated in early‑phase clinical trials for cervical cancer and other solid tumours.
What is CIGB 300 used for?
CIGB 300 is educationally associated with: Inhibition of CK2-driven pro-survival signaling, Induction of apoptosis in tumor cells, solid tumors, Antitumor activity in cervical cancer, Antitumor activity in non-small cell lung cancer, cervical cancer. Educational only — not medical advice.
How is CIGB 300 administered?
Recorded routes of administration: Intralesional, Intratumoral, Intravenous, Subcutaneous.
What are the potential side effects of CIGB 300?
Reported adverse effects include: Local Injection Site Reactions, Injection site pain, Fever / flu-like symptoms, Nausea, Fatigue, Hematologic toxicity. This list is not exhaustive — consult a qualified clinician.
Who should avoid CIGB 300?
Recorded contraindications: Severe hypersensitivity to peptide components, Severe hepatic or renal impairment, Pregnancy, Hypersensitivity to peptide. Consult a qualified clinician before use.